Published in N Engl J Med on November 08, 1973
Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med (1977) 7.01
An antigen capture enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients. J Clin Microbiol (2000) 4.00
C1q deviation test for the detection of immune complexes, aggregates of IgG, and bacterial products in human serum. J Exp Med (1975) 3.21
Dengue: defining protective versus pathologic immunity. J Clin Invest (2004) 2.73
Complement and meningococcal infection. Br Med J (1976) 2.28
Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J Exp Med (2006) 2.11
West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc Natl Acad Sci U S A (2006) 1.96
Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J Exp Med (2010) 1.76
Complement activation is required for induction of a protective antibody response against West Nile virus infection. J Virol (2005) 1.75
Association of increased platelet-associated immunoglobulins with thrombocytopenia and the severity of disease in secondary dengue virus infections. Clin Exp Immunol (2004) 1.66
Dengue virus-specific cross-reactive CD8+ human cytotoxic T lymphocytes. J Virol (1989) 1.55
Dengue viruses - an overview. Infect Ecol Epidemiol (2013) 1.40
Complement activation in children with acute malaria. Clin Exp Immunol (1974) 1.37
Circulating immune complexes in serum from patients with dengue haemorrhagic fever. Clin Exp Immunol (1979) 1.27
Consumptive opsoninopathy: possible pathogenesis in lethal and opportunistic infections. Ann Surg (1976) 1.27
Dengue: an arthropod-borne disease of global importance. Eur J Clin Microbiol Infect Dis (2004) 1.21
C5a-induced hemodynamic and hematologic changes in the rabbit. Role of cyclooxygenase products and polymorphonuclear leukocytes. Am J Pathol (1987) 1.18
Complement contributes to inflammatory tissue destruction in a mouse model of Ross River virus-induced disease. J Virol (2007) 1.17
Cryoglobulins, circulating immune complexes, and complement activation in cerebral malaria. Infect Immun (1981) 1.12
Replication of dengue and junin viruses in cultured rabbit and human endothelial cells. Infect Immun (1978) 1.12
Virus-specific cytolytic antibodies to nonstructural protein 1 of Japanese encephalitis virus effect reduction of virus output from infected cells. J Virol (2009) 1.10
Immune complexes in human diseases: a review. Am J Pathol (1980) 1.05
Infection-enhancing and -neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels. J Virol (2007) 1.05
Direct complement restriction of flavivirus infection requires glycan recognition by mannose-binding lectin. Cell Host Microbe (2010) 1.03
Complement abnormalities during an epidemic of group B meningococcal infection in children. Clin Exp Immunol (1986) 1.02
Retracted Dengue virus-induced apoptosis in hepatic cells is partly mediated by Apo2 ligand/tumour necrosis factor-related apoptosis-inducing ligand. J Gen Virol (2005) 1.00
Complement-mediated neutralization of dengue virus requires mannose-binding lectin. MBio (2011) 0.97
Complement and its role in protection and pathogenesis of flavivirus infections. Vaccine (2008) 0.96
Dengue Hemorrhagic Fever at 60 Years: Early Evolution of Concepts of Causation and Treatment. Microbiol Mol Biol Rev (2015) 0.96
Deficient IFN signaling by myeloid cells leads to MAVS-dependent virus-induced sepsis. PLoS Pathog (2014) 0.95
Complement requirement for virus neutralization by antibody and reduced serum complement levels associated with experimental equine herpesvirus 1 infection. Infect Immun (1981) 0.90
Mapping the interactions of dengue virus NS1 protein with human liver proteins using a yeast two-hybrid system: identification of C1q as an interacting partner. PLoS One (2013) 0.89
Kinetics of peripheral blood leukocyte alterations in Thai children with dengue hemorrhagic fever. Infect Immun (1980) 0.88
Immunofluorescent staining of the surfaces of lymphocytes in suspension from patients with dengue hemorrhagic fever. Am J Pathol (1976) 0.88
In vitro inactivation of complement by a serum factor present in Junin-virus infected guinea-pigs. Immunology (1980) 0.84
The importance of hematopoietic progenitor cells in dengue. Ther Adv Hematol (2012) 0.83
Role of complement in dengue virus infection: protection or pathogenesis? MBio (2012) 0.83
Dengue shock syndrome in Jamaica. Br Med J (1978) 0.83
Pathogenesis of Dengue: Dawn of a New Era. F1000Res (2015) 0.82
Pathogenic roles of macrophage migration inhibitory factor during dengue virus infection. Mediators Inflamm (2015) 0.81
Dengue fever in a Western United States City. West J Med (1977) 0.81
A highly conserved region between amino acids 221 and 266 of dengue virus non-structural protein 1 is a major epitope region in infected patients. Am J Trop Med Hyg (2014) 0.81
Dengue human infection models supporting drug development. J Infect Dis (2014) 0.79
Down-regulation of complement receptors on the surface of host monocyte even as in vitro complement pathway blocking interferes in dengue infection. PLoS One (2014) 0.77
C1q binding to dengue virus decreases levels of infection and inflammatory molecules transcription in THP-1 cells. Virus Res (2013) 0.76
Differential proteomic analysis of virus-enriched fractions obtained from plasma pools of patients with dengue fever or severe dengue. BMC Infect Dis (2015) 0.76
Immunoglobulin profiles provide new insights into infectious diseases. Yale J Biol Med (1983) 0.75
The Complement System in Flavivirus Infections. Front Microbiol (2017) 0.75
A method of trace iodination of proteins for immunologic studies. Int Arch Allergy Appl Immunol (1966) 43.66
Tularemia as a biological weapon: medical and public health management. JAMA (2001) 13.23
Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med (1978) 11.99
Murine models of systemic lupus erythematosus. Adv Immunol (1985) 9.79
Botulinum toxin as a biological weapon: medical and public health management. JAMA (2001) 9.18
Pathogenesis of the glomerulonephritis of NZB/W mice. J Exp Med (1968) 8.91
Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (2000) 8.45
The Raji cell radioimmune assay for detecting immune complexes in human sera. J Clin Invest (1976) 8.06
Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.96
Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med (1977) 7.89
Human monocytes: distinct receptor sites for the third component of complement and for immunoglobulin G. Science (1968) 7.70
Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J Exp Med (1969) 7.43
The C3-activator system: an alternate pathway of complement activation. J Exp Med (1971) 7.07
Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.06
C3 proactivator convertase and its mode of action. J Exp Med (1972) 6.94
The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med (1967) 6.81
Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement. J Exp Med (1967) 6.72
Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J Immunol (1970) 6.58
Pathogenesis of chronic disease associated with persistent lymphocytic choriomeningitis viral infection. I. Relationship of antibody production to disease in neonatally infected mice. J Exp Med (1969) 6.03
Complement. Annu Rev Biochem (1975) 6.00
A plaque reduction test for dengue virus neutralizing antibodies. J Immunol (1967) 5.78
The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement. J Exp Med (1968) 5.78
The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement. J Immunol (1968) 5.40
Enharncement of the hemolytic activity of the second component of human complement by oxidation. J Exp Med (1967) 5.36
Chemistry and reaction mechanisms of complement. Adv Immunol (1968) 5.02
Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. Proc Natl Acad Sci U S A (1978) 4.94
Autologous immune complex nephritis induced with renal tubular antigen. I. Identification and isolation of the pathogenetic antigen. J Exp Med (1968) 4.79
Etiopathogenesis of murine SLE. Immunol Rev (1981) 4.39
Shwartzman reaction after human renal homotransplantation. N Engl J Med (1968) 4.05
Lymphocytic choriomeningitis: production of antibody by "tolerant" infected mice. Science (1967) 4.01
Autologous immune-complex pathogenesis of experimental allergic glomerulonephritis. Science (1967) 3.96
The reaction mechanism of human C5 in immune hemolysis. J Exp Med (1970) 3.83
Experimental glomerulonephritis: immunological events and pathogenetic mechanisms. Adv Immunol (1967) 3.83
Increased spontaneous polyclonal activation of B lymphocytes in mice with spontaneous autoimmune disease. J Immunol (1978) 3.78
Serum transfer of collagen-induced arthritis in mice. J Exp Med (1983) 3.74
The second component of human complement: its isolation, fragmentation by C'1 esterase, and incorporation into C'3 convertase. J Exp Med (1968) 3.71
The pathogenesis of glomerulonephritis. Am J Med (1968) 3.61
Presence of anti-Sm reactivity in autoimmune mouse strains. J Exp Med (1978) 3.58
Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Invest (1970) 3.55
Endogenous oncornaviral gene expression in adult and fetal mice: quantitative, histologic, and physiologic studies of the major viral glycorprotein, gp70. J Exp Med (1976) 3.51
Complement. Annu Rev Biochem (1969) 3.51
Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A (1983) 3.47
Anaphylatoxins: C3a and C5a. Adv Immunol (1978) 3.44
Molecular biology and chemistry of the alternative pathway of complement. Adv Immunol (1980) 3.41
Autologous immune complex nephritis induced with renal tubular antigen. II. The pathogenetic mechanism. J Exp Med (1968) 3.40
Molecular analysis of the membrane attack mechanism of complement. J Exp Med (1972) 3.35
The effect of passively administered antibody on antibody synthesis. J Exp Med (1967) 3.31
Deficiency of the fifth component of complement in mice with an inherited complement defect. J Exp Med (1967) 3.28
Analysis of T cell function in autoimmune murine strains. Defects in production and responsiveness to interleukin 2. J Exp Med (1981) 3.27
Isolation of the anticomplementary protein from cobra venom and its mode of action on C3. J Immunol (1971) 3.25
C1q deviation test for the detection of immune complexes, aggregates of IgG, and bacterial products in human serum. J Exp Med (1975) 3.21
Lysis of erythrocytes by complement in the absence of antibody. J Exp Med (1970) 3.19
Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor. J Exp Med (1975) 3.12
Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int (1973) 3.09
Flaviviridae. Intervirology (1985) 3.06
The biology and detection of immune complexes. Adv Immunol (1979) 3.05
Hemolytic activity of lipoprotein-depleted serum and the effect of certain anions on complement. J Immunol (1966) 2.98
The ninth component of human complement: isolation, description and mode of action. Immunology (1969) 2.96
The reaction of monomeric and aggregated immunoglobulins with C1. Immunochemistry (1971) 2.96
Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med (1980) 2.94
Fourth component of human complement: description of a three polypeptide chain structure. J Exp Med (1974) 2.93
Studies on the mode of action of the fifth, sixth and seventh component of human complement in immune haemolysis. Immunology (1967) 2.93
Paroxysmal nocturnal hemoglobinuria. Hemolysis initiated by the C3 activator system. N Engl J Med (1972) 2.91
Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med (1981) 2.88
IgM rheumatoid factors in mice injected with bacterial lipopolysaccharides. J Immunol (1979) 2.86
Association of circulating retroviral gp70-anti-gp70 immune complexes with murine systemic lupus erythematosus. J Exp Med (1979) 2.86
Diagnosis of streptococcal pharyngitis: differentiation of active infection from the carrier state in the symptomatic child. J Infect Dis (1971) 2.83
The role of properdin in the alternate pathway of complement activation. J Exp Med (1974) 2.77
A spontaneous rheumatoid arthritis-like disease in MRL/l mice. J Exp Med (1982) 2.76
Deficiency of the sixth component of complement in rabbits with an inherited complement defect. J Exp Med (1966) 2.73
Isolation of a temperature-sensitive dengue-2 virus under conditions suitable for vaccine development. Infect Immun (1976) 2.67
Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J Exp Med (1976) 2.66
Mechanism and modification of rejection of heterografts between divergent species. Transplant Proc (1970) 2.63
Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology (1975) 2.62
The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J Immunol (1979) 2.58
Detection of additional antigenic determinants of hepatitis B antigen. J Immunol (1972) 2.57
The membrane attack complex of complement. Annu Rev Immunol (1986) 2.57
Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci U S A (1978) 2.57
Distribution of lymphocytes identified by surface markers in murine strains with systemic lupus erythematosus-like syndromes. J Exp Med (1979) 2.55
The antibody response of mice to murine leukemia virus in spontaneous infection: absence of classical immunologic tolerance (AKR mice-complement-fixing antibodies-lymphocytic choriomeningitis virus-immunofluorescence-glomerular deposits of antigen-antibody complexes). Proc Natl Acad Sci U S A (1972) 2.54
Bunyaviridae. Intervirology (1980) 2.53
Binding of soluble immune complexes to human lymphoblastoid cells. II. Use of Raji cells to detect circulating immune complexes in animal and human sera. J Exp Med (1974) 2.51
Formation of C3a and C5a anaphylatoxins in whole human serum after inhibition of the anaphylatoxin inactivator. J Exp Med (1973) 2.50
Dengue virus identification by the plaque reduction neutralization test. J Immunol (1967) 2.45
A comparison of methods for the molecular quantitation of the fourth component of human complement. Immunochemistry (1968) 2.44
The membrane attack mechanism of complement. Verification of a stable C5-9 complex in free solution. J Exp Med (1973) 2.44
Transfer of ovine experimental allergic glomerulonephritis (EAG) with serum. J Exp Med (1966) 2.42
Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci U S A (1986) 2.39
Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins. J Exp Med (1979) 2.39
Histocompatibility-linked genetic control of disease susceptibility. Murine lymphocytic choriomeningitis virus infection. J Exp Med (1973) 2.39
Humoral antibodies and coagulation mechanisms in the accelerated or hyperacute rejection of renal homografts in sensitized canine recipients. Surgery (1970) 2.38
The oncornavirus glycoprotein gp69/71: a constituent of the surface of normal and malignant thymocytes. J Exp Med (1975) 2.37
M antigens among group A streptococci isolated from skin lesions. J Exp Med (1967) 2.35
Formation of transmembrane tubules by spontaneous polymerization of the hydrophilic complement protein C9. Nature (1982) 2.35
Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med (1972) 2.33
Clotting changes, including disseminated intravascular coagulation, during rapid renal-homograft rejection. N Engl J Med (1970) 2.33